Form 4 for XLO Xilio Therapeutics, Inc.

Accepted 2021-10-26 00:00:00 ET · period of report 2021-10-26 · accession 0001722024-21-000012 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2021-10-26	2021-10-26	XLO	Alexandria Venture Investments, LLC	10%	C - Cnv Deriv	—	+166.4K	166.4K	New	—
D	2021-10-26	2021-10-26	XLO	Alexandria Venture Investments, LLC	10%	C - Cnv Deriv	—	-1.58M	0	-100%	—

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common stock	2021-10-26	C	A	166,423	—	166,423	D	—	—	(F1) Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 9.5 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on October 22, 2021, for no additional consideration. The shares had no expiration date.
2	Derivative	Series B convertible preferred stock	2021-10-26	C	D	1,581,026	—	0	D	— · — to —	166,423 Common stock	(F2) Not applicable. (F1) Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 9.5 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on October 22, 2021, for no additional consideration. The shares had no expiration date.